Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation

Summary

Primary Objective: \- Explore Dronedarone and active metabolite pharmacokinetic (PK) profiles according to different timings of Dronedarone initiation. Secondary Objective: * Explore potential PK interaction between Dronedarone and Amiodarone * Evaluate the rate of Atrial Fibrillation (AF) recurrence during the study period (from randomization up to 60 days after) * To assess the safety of the change from Amiodarone to Dronedarone and Dronedarone safety

Timeline

Start

2010-10

Primary completion

2012-04

Completion

2012-04

Publications

• Naccarelli GV, Bhatt DL, Camm AJ, Le Heuzey JY, Lombardi F, Tamargo J, Martinez JM, Naditch-Brule L; ARTEMIS AF Investigators. Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):425-437. doi: 10.1177/1074248420926874. Epub 2020 Jun 5.

Drugs

Indications